Spots Global Cancer Trial Database for Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Official Title: A Phase III Study to Compare HS627 vs. Pertuzumab on the Efficacy, Safety and Immunogenicity in Combination With Trastuzumab and Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2 Positive Breast Cancer
Study ID: NCT04514419
Conditions
Study Description
Brief Summary: The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Detailed Description: A multicenter, randomized, double-blind, positive drug parallel control design was used. The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks). All eligible subjects were randomly divided into experimental group (hs627 treatment group) and control group (pertuzumab) treatment group. After 4 treatment cycles, the subjects arranged surgical treatment, and then conducted the last visit.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Contact Details
Name: Zefei Jiang, M.D
Affiliation: The Affiliated Hospital of Qingdao University
Role: PRINCIPAL_INVESTIGATOR
Name: Haibo Wang, M.D
Affiliation: The Affiliated Hospital of Qingdao University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
